CASI Pharmaceuticals Inc. (CASI)
(Delayed Data from NSDQ)
$6.47 USD
-0.07 (-1.07%)
Updated Sep 20, 2024 02:55 PM ET
After-Market: $6.27 -0.20 (-3.09%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
CASI 6.47 -0.07(-1.07%)
Will CASI be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CASI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CASI
VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Tops Revenue Estimates
Ironwood Pharmaceuticals (IRWD) Reports Break-Even Earnings for Q2
CASI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
CASI Pharmaceuticals (CASI) Up on Buyout Offer for China Business
USANA Health Sciences (USNA) Q3 Earnings Miss Estimates
Other News for CASI
Novartis expands U.S. radiopharma production amid rising competition
CASI PHARMACEUTICALS TO PARTICIPATE IN THE 2024 H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE
CASI Stock Earnings: CASI Pharmaceuticals Beats EPS, Misses Revenue for Q2 2024
CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2024 BUSINESS AND FINANCIAL RESULTS
CASI Pharmaceuticals Shifts Focus, Garners Investment